Hypervascular Uterus — Overview and Treatment

Common Causes and Their Treatments

1. Uterine Arteriovenous Malformation (AVM)

• Selective uterine artery embolization (UAE) — first-line definitive treatment. On selective angiography, early venous return is demonstrated and the lesion is treated with selective embolization. — Grainger & Allison's Diagnostic Radiology
• Conservative management can be attempted for small/asymptomatic AVMs
• Hysterectomy reserved for refractory, life-threatening hemorrhage

2. Uterine Fibroids (Leiomyomas) — Most Common Cause

Medical Management (for symptom control / pre-surgical optimization)

Surgical Management

• Myomectomy (abdominal, laparoscopic, or hysteroscopic) — fertility-preserving; vasopressin injected intraoperatively to limit blood loss
  • Blood loss reduction strategies: vaginal misoprostol (~98 mL reduction), intramyometrial vasopressin (~246 mL reduction), tourniquets
  • ~10% risk of clinically significant new fibroid appearance at 5 years post-myomectomy
• Hysterectomy — definitive; indicated when fertility not desired and symptoms are severe

Interventional Radiology

• Uterine Artery Embolization (UAE): Effective, less invasive alternative to surgery
  • Technique: femoral artery access → catheterization of uterine arteries → embolization with PVA particles, gelatin sponges, or tris-acryl gelatin microspheres until occlusion
  • Fibroid + uterine volume significantly reduced; persists up to 5 years (EMMY trial)
  • ~28% of women required subsequent hysterectomy within 5 years
  • Contraindications: active genital infection, genital tract malignancy, immunosuppression, severe vascular disease, contrast allergy, renal impairment, women planning future fertility (relative)
  • Total radiation exposure ~15 cGy (comparable to 1–2 CT scans)

Emerging/Minimally Invasive

• MRI-guided focused ultrasound (MRgFUS) — non-invasive thermablative technique; safe and feasible for selected fibroids
• Endometrial ablation — palliative for bleeding only (not fibroid-specific)

3. Retained Products of Conception (RPOC)

• Surgical evacuation (suction curettage or hysteroscopic removal) — first-line
• Expectant/medical management with misoprostol in hemodynamically stable patients
• If AVM suspected concurrently: embolization before or instead of surgical evacuation

4. Gestational Trophoblastic Disease (GTD)

• Hydatidiform mole: Suction curettage; serial β-hCG monitoring
• Gestational trophoblastic neoplasia (GTN): Chemotherapy — single-agent (methotrexate or actinomycin-D for low-risk) or multi-agent regimens (EMA-CO for high-risk)
• Hysterectomy in select cases (older patient, completed childbearing, localized disease)

5. Placenta Accreta Spectrum

• Planned cesarean hysterectomy (leaving placenta in situ) at a tertiary center
• Pre-operative uterine artery embolization or balloon occlusion to reduce blood loss
• Conservative (uterus-preserving) management in highly selected cases

Summary: Treatment Decision Framework

Hypervascular Uterus in the Setting of PID

Why PID Causes Uterine Hypervascularity

• Endometritis: the endometrium becomes thickened (≥14 mm), with a poorly defined endometrial/myometrial interface and fluid within the endometrial cavity. The myometrium may be hypoechoic due to oedema and inflammation.
• Abnormal endometrial enhancement on CT/MRI and increased color Doppler signal reflect the hyperemic, inflamed uterus.
• In early PID, the uterus may appear normal or slightly enlarged with ill-defined margins from pelvic exudate. As the disease progresses, the hypervascular appearance intensifies.

Etiology of PID

Diagnostic Criteria

• Uterine tenderness, OR
• Adnexal tenderness, OR
• Cervical motion tenderness

• Fever > 38.3°C
• Mucopurulent cervical/vaginal discharge
• Elevated ESR or CRP
• PMNs on vaginal wet prep
• NAAT positive for gonorrhea or chlamydia
• Endometrial biopsy showing endometritis

Treatment

Outpatient Regimen (mild–moderate disease)

Parenteral Regimen (hospitalized patients)

• Cefotetan 2 g IV q12h (or Cefoxitin 2 g IV q6h)
• + Doxycycline 100 mg IV or PO q12h
• → Continue until 48 h after clinical improvement → complete 14-day oral course with doxycycline

• Clindamycin 900 mg IV q8h
• + Gentamicin (loading 2 mg/kg IV/IM, then 1.5 mg/kg q8h)
• → Step down to oral doxycycline 100 mg BID or clindamycin 450 mg QID to complete 14 days
• Use clindamycin (not doxycycline) for step-down when tubo-ovarian abscess (TOA) is present — better anaerobic coverage

If M. genitalium suspected/confirmed:

• Moxifloxacin 400 mg PO daily × 14 days (if macrolide resistance present or suspected)

Indications for Hospitalization

• Cannot exclude acute surgical abdomen (appendicitis, ectopic)
• Tubo-ovarian abscess (TOA) present
• Pregnancy
• Immunodeficiency
• Severe illness / high fever
• Unable to tolerate oral antibiotics
• No response to outpatient therapy within 72 hours
• Follow-up cannot be ensured

Surgical Indications in PID

• Ruptured or threatened TOA (life-threatening) — emergency laparotomy or laparoscopy
• Drainage of abscess not responding to antibiotics — posterior colpotomy or percutaneous drainage (US/CT-guided)
• Diagnostic laparoscopy — when diagnosis is uncertain or unilateral pain/mass raises concern for surgical emergency (appendicitis, ectopic pregnancy)

Conservative surgical procedures are generally sufficient; pelvic abscesses can often be drained by posterior colpotomy, and peritoneal lavage used for generalized peritonitis. — Harrison's Principles of Internal Medicine 22E, p. 1150

IUD Consideration

• IUD need not be routinely removed for mild-to-moderate PID
• If no clinical improvement within 72 hours of antibiotics, remove the IUD
• Actinomycosis is specifically associated with long-standing IUD use — produces a solid, infiltrating pelvic mass (not typical fluid abscess) on imaging

Complications / Late Sequelae

Partner Management